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Molecular Basis of Mitomycin C Resistance
in Streptomyces: Structure and Function
of the MRD Protein
is opened, conferring high reactivity on the sp2 carbon
C1. In this activated form, MC monoalkylates the 2-NH2
group of guanines in the minor groove via the C1 carbon
and may form intra- and interstrand cross-links at both
the C1 and C10 positions [8] (Figure 1B). Since cells
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Two proteins in S. lavendulae that are products ofMitomycin C (MC) is a potent anticancer agent. Strep-
the mcrA and mrd genes have been shown to confertomyces lavendulae, which produces MC, protects it-
resistance to MC [13–15]. MCRA (54 kDa) has a cova-self from the lethal effects of the drug by expressing
lently bound FAD cofactor and acts by oxidizing theseveral resistance proteins. One of them (MRD) binds
activated (reduced) MC before it can bind DNA [16]. InMC and functions as a drug exporter. We report the
contrast, MRD, a 14 kDa, single chain protein, interactscrystal structure of MRD and its complex with an MC
with MC itself and functions as a component of a drug-metabolite, 1,2-cis-1-hydroxy-2,7-diaminomitosene,
exporting pathway [15]. Recent work indicates that MRDat 1.5 A˚ resolution. The drug is sandwiched by-stack-
works in conjunction with a membrane-associated pro-ing interactions of His-38 and Trp-108. MRD is a dimer.
tein (MCT) to expel MC from the cell [17]. Both the mrdThe  fold of the MRD molecule is reminiscent of
and mct genes are found within the MC biosyntheticmethylmalonyl-CoA epimerase, bleomycin resistance
gene cluster in S. lavendulae [18].proteins, glyoxalase I, and extradiol dioxygenases. The
Clinical research suggests potential applications forlocation of the binding site is identical to the ones
proteins with functions similar to those of MRD andin evolutionarily related enzymes, suggesting that the
MCRA. A genetic therapy protocol involving the biore-protein may have been recruited from a different meta-
ductively-activated alkylating agent CB-1954 was re-bolic pathway.
cently approved for phase I/II studies by the FDA [19].
The protocol involves transfection of the gene for an
Introduction activating enzyme (nitroreductase) selectively to tumor
cells, thereby sensitizing them to chemotherapy.
Mitomycin C (MC, MW 331) is a highly cytotoxic, DNA- Healthy somatic cells, which would only be exposed to
reactive antibiotic produced by Streptomyces lavendu- the prodrug form of CB-1954, could therefore be spared
lae [1]. Approved by the Food and Drug Administration harmful side effects. A future application of proteins
as an anticancer drug in 1974, MC has been used widely similar to MRD and/or MCRA might conceivably work in
and continues to be of use in the treatment of bladder, an inverse manner, providing healthy cells with specific
head and neck, cervical, gastric, pancreatic, and colon resistance to MC [20] and allowing for a much more
cancers [2–4]. In its prodrug form (Figure 1A), MC does aggressive treatment of tumors than is presently pos-
not bind to DNA and becomes biologically active only sible.
after reductive conversion to a short-lived and highly Structural characterization of the MRD resistance pro-
reactive quinone methide [5–7]. The latter compound tein was pursued to explore the molecular basis of MC
lacks the methoxide substituent, and the aziridine ring
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Figure 1. The Chemistry of Mitomycin C
(A) Mitomycin C (NSC 26980 in the National
Cancer Institute database).
(B) Formation of covalent DNA cross-links oc-
curs via bonding at C1 and C10.
(C) 1,2-cis-1-hydroxy-2,7-diaminomitosene.
drug binding and transport. Herein we describe the mo- Though the quality of the model based on the 1.3 A˚
lecular architecture of the native MRD protein and the SeMet dataset was good, the density presumed to cor-
structural details of the complex of MRD with 1,2-cis- respond to the ligand was deemed unsatisfactory.
1-hydroxy-2,7-DAM, which binds to MRD with an asso- Therefore, the experiment was repeated, and 1.5 A˚ reso-
ciation constant that is five times higher than that of lution data were collected from another SeMet-con-
MC. MRD is a dimer, with each monomer containing a taining crystal that was soaked for a longer period in
tandem repeat of  modules. Two different modes the presence of MC. Subsequent refinement against
of dimer formation are observed, suggesting a domain- these data revealed full occupancy for a bound ligand,
swapping event. The drug binding sites are located in which proved to be 1,2-cis-1-hydroxy-2,7-DAM (see be-
deep clefts on the opposite sides of the molecule and low for further details of the chemistry). The final, refined
formed either by the curvature of the  sheet within a model of the complex is derived from this 1.5 A˚ data
monomer or, when domain swapping occurs, by two set.
 modules from adjacent monomers. The drug is In all three crystal structures, a single monomer occu-
sandwiched by -stacking interactions between the pies the asymmetric unit of the C2 unit cell, and two
protonated imidazole of His-38 and the indole ring of monomers form a close association with the resultant
Trp-108. 2-fold axis of the MRD dimer corresponding to the crys-
tallographic dyad. This is consistent with our gel filtra-
Results and Discussion tion results (data not shown), which indicate that a dimer
is the predominant species in solution. For all three
Structure Determination and Model Quality
refined models, each monomer contains residues 3–130,
MRD was overexpressed in E. coli, purified, and crystal-
inclusive, with the region containing residues 65–71 be-
lized as described in Experimental Procedures. The use
ing comparatively less well ordered. Residues in thisof the MAD phasing technique based on SeMet was
region were not included until final refinement, for rea-limited due to the presence of only one Met residue.
sons explained below. There are 153, 161, and 158 or-Therefore, we designed a double mutant in which Leu-
dered water molecules included in the final models for19 and Leu-25 were replaced by methionine residues.
the ligand-bound, apo form, and 1.3 A˚ resolution struc-Crystals of the SeMet containing double mutant dif-
tures, respectively. In the case of the complex structure,fracted beyond 1.3 A˚ resolution (see Table 1). For experi-
a molecule of 1,2-cis-1-hydroxy-2,7-DAM was modeledmental phasing, we used a single data set collected at
into residual positive difference electron density andthe absorption peak of Se (0.979 A˚) from a crystal soaked
included late in refinement. The known geometry of thefor two days in the mother liquor containing MC (see
quinone ring was used as a restraint, while the remainingExperimental Procedures). The positions of the three
moieties were restrained using standard bond lengthsmethionine residues were readily determined and al-
and angles.lowed for the calculation of preliminary phases. The
The quality of the models, as judged by stereochemi-initial model was created using ARP/wARP [21], which
cal criteria, is high (see Table 2), and PROCHECK [23]automatically built 110 out of a total of 130 residues,
analysis indicates that approximately 95% of the resi-and refined with SHELXL [22]. Additionally, a complete
dues in the final models are in the most favored regionsdata set to 1.5 A˚ was first collected from a crystal of
the wild-type and unliganded protein. with no outliers.
Table 1. X-Ray Experimental Data
Apo-MRD Partial Ligand Occupancy Full Ligand Occupancy
Resolution (A˚) 1.5 1.3 1.5
Number of reflections
Total 74,125 119,032 66,770
Unique 17,820 27,880 18,054
Redundancy 4.15 4.26 3.64
Completeness (%) 99.9 (99.4)a 99.9 (99.6) 99.9 (100.0)
Rsym (%)b 3.4 (33.5) 6.8 (34.2) 4.6 (30.1)
I/ ratio 36.1 (3.6) 13.9 (3.4) 26.3 (4.0)
a The numbers in parentheses describe the relevant value for the last resolution shell.
b Rsym |Ii  I|/I, where Ii is the intensity of the ith observation and I is the mean intensity of the reflections.
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Table 2. Refinement Details
Partial Ligand Occupancy Full Ligand Occupancy Apo-MRD
Resolution used in final refinement (A˚) 10.0–1.3 10–1.5 10.0–1.5
Rcryst/Rfree (%)a 16.1/22.9 13.6/20.9 16.8/23.4
Rmsd from target bond lengths (A˚)/bond angles (	) 0.017/2.09 0.018/2.14 0.016/1.8
Rmsd from B (A˚2) overall 2.11 2.38 2.41
Average B factors (A˚2)
Main chain atoms 19.28 22.25 23.26
Side chain atoms 23.57 26.90 26.27
Waters 39.63 42.76 44.8
a Rcryst 
 |Fo  Fc|/|Fo|, where Fc is the calculated structure factor.
MRD Is a Member of a Diverse Family Tandem  motifs have been observed in several
other proteins with diverse functions. They originallyof  Proteins
MRD is an oblong dimer with dimensions of roughly included the bleomycin resistance protein from Strep-
toalloteichus hindustanus (ShBle) [24], two extradiol di-50  40  30 A˚ (Figure 2B). Each monomer is made up
of an eight-stranded  sheet, with each sheet comprised oxygenases [25, 26], and glyoxalase I [27]. These struc-
tures were quickly recognized to be representative of aof two  motifs (domains) packed edge to edge,
so that the first strands of the two modules are associ- larger family [28]. More recently, additional members
were described: the bleomycin resistance proteinsated in an antiparallel manner. The basic topology in
each domain is a four-stranded  sheet (defined as 1, found in Streptomyces verticillus (BLMA) [29] and on
transposon Tn5 in E. coli (BLMT) [30], a methylmalonyl-4, 3, and 2) with an  helix connecting strands 1
and 2 (Figure 2A). Domain A consists of residues 3–53, coenzyme A epimerase (MMCE) from P. shermanii
[31], and several more dioxygenases and glyoxalasesand domain B consists of residues 74–130, while resi-
dues 54–73 form the connecting region, including a short [32–35].
Of particular interest is the structural similarity be- helix. In spite of lack of identifiable sequence similarity
between the two domains, their tertiary structures are tween MRD and the bleomycin resistance proteins
(BRPs). As with MC, bleomycin is an antibiotic and DNAvery close. A superposition of the two modules in MRD
yields 38 pairs of C atoms with a root-mean-square cleaving agent but is chemically unrelated. However,
there is some identifiable, albeit low, amino acid se-(rms) difference of 1.6 A˚.
Figure 2. The Structure of MRD Protein
(A) Topology of the MRD monomer. Domain
A, pink; domain B, red.
(B) Stereoview of the C tracing of the MRD
dimer.
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Figure 3. Structure-Based Sequence Align-
ment of MRD with Bleomycin Resistance Pro-
teins ShBle (1BYL), BLMT (1ECS), and BLMA
(1QTO)
The two key residues involved in sequester-
ing the drug are boxed in red; the five invariant
residues in the sequences are boxed in green.
quence similarity between MRD and the BRPs (Figure The family of proteins to which MRD belongs is recog-
3). This similarity extends to the level of structure: the nized for a history of gene duplication and domain-
first  motifs of MRD and ShBle (1BYL in PDB) swapping events [28, 31, 36]. The original gene duplica-
superpose with 28 C atom pairs yielding an rms differ- tion event led to the  tandem structure, which
ence of 2.4 A˚, while the C-terminal motifs match even appears to require dimerization for stability. Owing to
better, with 53 C pairs, i.e., essentially the entire do- the nature of the dimer, in which the connecting linkers
mains, superposing with an rms difference of 1.9 A˚. Even are close together, two alternative modes of dimeriza-
more striking is the similarity between MRD and BLMA tion are possible. Interestingly, while MMCE conforms
(1QTO): the first domains superpose with 42 C pairs to one of these (form I), BRPs and human glyoxalase
with an rms difference of 1.8 A˚, and the second yield exemplify the other (form II), and the two groups were
53 pairs and an rms difference of 1.9 A˚. contrasted in literature as evidence of evolutionary 3D
Other proteins in this family are also structurally simi- domain swapping [28]. Further duplication is observed
lar. The MMCE molecule displays particular similarity to in dioxygenases, where two tandems are covalently
MRD in the second  motif, for which a superposi- linked to form a sequential 4-fold repeat of the 
tion of 49 C atoms yields an rms difference of 1.6 A˚. module. The MRD structures, on the other hand, appear
The prevailing pattern, noted by previous authors [28, to suggest that the domain-swapping events may be
31], is that the N-terminal modules superpose on each dynamic, so that the two forms may coexist in solution,
other better than on the C-terminal motifs and vice versa. while crystallization selectively isolates either one or
Although in all three structures the MRD dimer con- the other. Whether this is a consistent feature of other
sists of two pairs of domains A and B related by crystal- proteins in the family remains to be seen.
lographic symmetry, alternative connectivities between
these domains give rise to two topologically distinct
The Bound MC Derivative Is 1,2-cis-1-Hydroxy-forms generated by a 3D domain-swapping phenome-
2,7-DAMnon. Our electron density indeed corroborates that both
MRD crystals turn pink when soaked for a few days inspecies are present, albeit each crystal form selects
mother liquor solution containing crystalline MC. Be-preferentially for one. In form I, observed in wild-type
cause MC is purple, with a visible absorbance spectrumunliganded MRD, each monomer consists of a continu-
showing a single peak at 360 nm, the pink color sug-ous eight-stranded sheet, and the back to back interface
gested the appearance of a compound closely related tobetween the eight-stranded sheets establishes the inter-
2,7-diaminomitosene, with a characteristic absorbanceface between the two monomers. In form II, found in both
peak at 313 nm. The initial 1.3 A˚ data set, derived fromdrug-bound SeMet-containing crystals, each monomer
crystals soaked for two days, yielded a region of densitycontributes half of each of the two eight-stranded sheets
suggestive of a bound ligand, albeit of poor quality. Thein the dimer (Figure 4). The structural differences be-
1.5 A˚ data set, obtained from a crystal soaked for fourtween these forms result from a simple change in the
days, yielded very well-defined electron density for thelinker connecting the two domains. In form I, residues
bound drug. We noted that there was no electron density67–69 form two turns, which face each other as symme-
associated with the methoxy substituent at C9a of MC,try-related structures. In form II, proline 67 and threonine
and the region corresponding to C9 carbon clearly68 are in an extended conformation and form two linear
strands going in opposite directions. showed the flattened sp2 hybridization, with the substit-
Structural Analysis of the Mitomycin C Resistance Protein
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Figure 4. The Two Topological Forms of the MRD Dimer
Form I and form II are on the left, close-ups of their respective “crossover” region are in the center, and schematic diagrams of the  strands
(represented perpendicular to the page) are on the right. In form I, each  sheet is created by a single monomer (A connected to B), while,
in form II, each sheet is composed of the A domain from one monomer and the B domain of the other (A connected to B). For each protein,
one monomer is shown with its first domain pink and its second domain red (the convention used in Figure 2), while the other monomer is
shown with its first domain yellow and its second domain gold. The electron density shown is from omit maps, with the three relevant residues
removed for several rounds of least-squares refinement.
uent in the plane of the quinone, rather than the tetrahe- with and without addition of MRD. We conclude that
under the conditions of our experiments, MRD is notdral sp3 geometry associated with MC (Figure 5A). Fur-
ther, there was clear evidence (as judged from the involved in the hydrolytic transformation of MC, which
occurs in solution due to general acid/base catalysis.electron density) of the opening of the aziridine ring with
two substituents in positions 1 and 2 in cis configuration. The structural analysis of MRD shows that its drug
binding site is located within a deep cleft formed by theAll these details are consistent with 1,2-cis-1-hydroxy-
2,7-DAM, and not MC, being bound to MRD. For final curved eight-stranded  sheet, with the flat hydroqui-
none moiety of 1-hydroxy-2,7-DAM packing tightly intorefinement a set of model constraints, based on the
known crystal structure of MC, was used [37]. a “slot” created by the side chains of residues His-38
and Trp-108 (see below for further details). The presenceSince 1,2-cis-1-hydroxy-2,7-DAM is a reaction prod-
uct derived from either reduction or acid hydrolysis of of a tryptophane in the binding site allowed us to mea-
sure the dissociation constants (Kd) for MC and 1-hydroxy-MC, we decided to determine whether MRD has cata-
lytic properties under the conditions used to generate 2,7-DAM using fluorimetric titration. The dissociation
constant for MC determined in this way is 31 M, whilecrystals. We monitored the stability of MC in solution by
measuring absorption spectra in the visible wavelength that for 1-hydroxy-2,7-DAM shows tighter binding—6.3
M. This shows that the integrity of the aziridine ringrange. The hydrolysis of MC to 1-hydroxy-2,7-DAM is
accompanied by a change of spectrum with excellent and the methoxide group of MC are not required for
efficient binding and that MRD is capable of bindingisosbestic points at 330 and 240 nm, indicating that no
intermediates are involved [12], and the reaction is easily both MC and its immediate reaction product.
followed by spectrophotometric means. Our data (data
not shown) indicate that MC is stable in 100 mM MES The Drug Binding Site
The symmetry-related binding pockets are located onbuffer at pH 6.0 in both the presence and absence of
MRD. However, the addition of 65% saturated ammo- opposite sides of the dimer. In form I, each binding
cavity is created by the bent, or “cup”, structure of thenium sulfate results in the hydrolysis of MC to 1,2-cis-
1-hydroxy-2,7-DAM over a period of hours to days, again eight-stranded  sheet of each monomer. In form II, the
Structure
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Figure 5. The Binding of 1,2-cis-1-Hydroxy-
2,7-DAM to MRD
(A) Electron density and a model of the bound
1,2-cis-1-hydroxy-2,7-DAM molecule. The
density shown was generated using an omit
map, with ligand model removed before sev-
eral rounds of refinement.
(B) Two views of the bound form of the MRD
dimer, again in form II, with helices in red and
 sheets in light blue. The DAM molecule is
depicted in yellow.
 sheet is created from four strands from each monomer, molecules within the cavity. The specific binding of this
amidoacetate group appears important because the dis-and the binding pocket is therefore also composed
partly from one monomer and partly from the other (Fig- sociation constant for MC of the Y112F mutant, in which
one of the hydrogen bonds is removed, is 0.4 mM, anure 5B). Regardless of the topological differences be-
tween the two forms, the chemistry of the binding site order of magnitude higher than that of the wild-type
protein. There is also an H bond network involving theremains the same.
The most noticeable feature of the substrate binding hydroxy oxygen (designated O0 in the model) and the
amino nitrogen N1 (which is an aziridine nitrogen in MC).region is the outer rim, where the flat hydroquinone
moiety of DAM packs tightly into a slot created by the This network involves a water molecule that forms bonds
with both the O0 oxygen and the N1 nitrogen. Two otherimidazole of His-38 and the indole ring of Trp-108. It is
interesting to note that His-38 remains protonated and residues, Tyr-60 and Asp-52, each form a hydrogen
bond with the N1 nitrogen as well. The negative chargecharged, due to two interactions with carboxylates, one
with Asp-52 through N1 and one with Glu 40 via N2. on Asp-52 is not critical because the D52N mutant binds
MC with affinity virtually identical to the wild-typeBoth are short H bonds with 2.6 A˚ distances. The imada-
zole (His-38) and the five-membered portion of the in- protein.
The overall arrangement of residues in wild-type unli-dole (Trp-108) face each other, with their centers
approximating a common axis for both rings. The hydro- ganded MRD is not significantly different from the drug-
bound form. The distance between His-38 and Trp-108quinone moiety is sandwiched between these two rings,
so that the C8a carbon packs between the centers of is slightly larger in the native form, so the cleft between
them appears to narrow when packed with the DAMthe rings. A nearly straight line can be drawn from the
C1 carbon of the histidine through the C8a carbon of quinone. The space occupied by the ligand in the com-
plex is filled by approximately eight ordered water mole-the quinone to the C carbon of the tryptophan. The
total separation is 7.0 A˚, with the C8a situated almost cules in the unliganded form of the protein. The overall
arrangement of the hydrogen bonding network, particu-precisely in between, at a distance of 3.5 A˚ from the
other two atoms (Figure 6A). larly one involving Asp-52 and Tyr-60, can be see in
Figure 6B. The bound 1,2-cis-1-hydroxy-2,7-DAM doesThe region of the DAM molecule corresponding to the
location of the aziridine ring in MC makes contact with not induce any significant structural changes in the MRD
protein.residues in the interior of the protein, while the opposite
side is exposed to bulk solvent. The C9 substituent is
held in place by a set of hydrogen bond interactions, Comparison with BRPs
As already pointed out, MRD shares its overall tertiarynotably the terminal N14 nitrogen with Tyr-112 and the
terminal O13 oxygen with Gln-110, and by two water and quaternary structure with BRPs, which also have a
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Figure 6. The Stereochemical Details of the
Binding Site
(A) Stereoview of DAM within the binding
region.
(B) Stereoview of the water structure inside
the binding cavity of the native form.
pair of symmetric cavities that serve as binding sites, by the bleomycin resistance proteins and MRD is very
similar.but there are substantial differences between the two
target drugs. Bleomycin, the ligand for BRPs, is a far
larger molecule than MC and chemically unrelated. It
contains several chemical groups, including bithiazole, Biological Implications
methylvalerate threonine linker, and metal binding and
sugar moieties. Recently, a crystallographic study re- The study reported in this paper describes the high-
resolution crystallographic study of the MRD resistancevealed the structural details of the BLMT-Bm complex
[30]. The linker, metal binding, and sugar groups of Bm protein in complex with a derivative of the cancer drug
mitomycin C. The MRD dimer is believed to be part ofinteract with numerous amino acids within a shallow
surface groove, but the bithiazole moiety, made up of a drug transport system that shuttles the MC molecule
out of the drug-producing organism Streptomyces la-two five-membered rings, is sequestered between two
tryptophanes, i.e., Trp-99 and Trp-35, which correspond vendulae. The protein is a member of a larger family of
enzymes and drug binding molecules characterized byto Trp-108 and His-38 of MRD. The loops containing
these crucial residues have virtually identical stereo- a conserved  motif as a principle module. The
quinone moiety of the bound 1,2-cis-1-hydroxy-2,7-DAMchemistries in the two proteins, although the details of
the interaction with ligand vary (Figure 7). Trp-108 of is sandwiched between the imidazole of His-38 and the
indole of Trp-108. Affinity measurements show that bothBLMT has the indole ring rotated nearly 180	 around 2,
as compared to MRD, and Trp-35 has the five-mem- mitomycin C and 1-hydroxy-2,7-DAM bind with similar
dissociation constants (in the M range). The bindingbered ring nearly overlapping with the imidazole of His-
38 when the two models are overlapped. The distance mode is similar to that observed for the bleomycin resis-
tance protein, where a bithiazole moiety is sequesteredbetween the two parallel indoles is about 7 A˚. The first
thioazole group of Bm interacts only with Trp-108, while between two tryptophan residues that occupy sites
equivalent to those of Trp-108 and His-38 in MRD. Thisthe second thiozole is sequestered by both indoles.
BLMT binds Bm with a dissociation constant of 32 nM, suggests that the  proteins are promiscuous in
their interactions with ligands and could be engineeredbut it is not known whether bithiazole binds on its own
and with what affinity. Thus, even though the nature of to bind a diverse set of planar molecules of biological
importance.the ligand is very different, the mode of drug binding
Structure
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Figure 7. The Comparison of the BLMT and
MRD Binding Sites
The 1,2-cis-1-hydroxy-2,7-DAM molecule
and the bithiazole of BM are shown with the 
carbons of the two sequestering amino acids
superposed on each other.
Experimental Procedures Binding Assays
Dissociation constants (Kd) were determined by fluorimetric titration
of MRD wild-type and its two mutant forms (D52N and Y112F) withExpression of MRD in E. coli
The mrd gene was subcloned into an expression vector used to increasing concentrations of drug (MC or DAM). To determine the
dissociation constant, increasing amounts of the drug were addedcreate a GST fusion protein with an rTEV proteolytic cleavage site
(pGST-Parallel1) [38]. Aggregation difficulties with the MRD-GST to a constant concentration of the MRD. In each case eight to ten
data points were collected. Experiments were done in duplicate atfusion protein led us to test samples using size exclusion chroma-
tography. This provided early evidence that MRD was a dimer and 20	C using an FP-750 spectrofluorometer (Jasco) under the follow-
ing conditions:  excitation 
 280 nm,  emission 
 342 nm, andthat higher-order oligomers of MRD-GST were responsible for ag-
gregation. The mrd gene was then subcloned into a His6-tag expres- excitation and emission slit width 
 5 nm. MC or 1-hydroxy-DAM
(2 M–0.7 mM) were added to 1200 l of 1.8 M MRD in 100 mMsion vector (pHis Parallel1) [38]. The sequence-verified plasmid was
transformed into E. coli BL21(DE3) (Novagen). The cells were grown MES (pH 6.0). The residual protein fluorescence was measured after
100 min incubation. The dissociation constants were determined asat 37	C in 1 liter of LB broth containing 100 g/ml ampicillin to an
OD600 of 0.6–0.8, and expression was initiated by the addition of described previously [39]. The protein concentration was estimated
using the molar absorbance coefficient 280 
 28,226 M1 cm1 forIPTG to a final concentration of 1 mM. The culture was grown for
an additional 3 hr at 37	C. The cells were harvested by centrifugation MRD WT and MRD D52N and 280 
 27,028 M1 cm1 for MRD Y112F,
calculated from the number of Trp and Tyr residues in the MRDat 8,000  g for 10 min at 4	C. The pellet was resuspended in ice-
cold His buffer (5 mL/g; 300 mM NaCl and 50 mM Tris-HCl [pH 8.5]) molecule [40]. The MC concentration contained in solution was esti-
mated using the molar absorbance coefficient 367 
 21,840 M1and sonicated on ice using five 30 s bursts with a 5 min cooling
period between each burst. The cellular debris was pelleted by cm1. The DAM concentration was determined using the molar ab-
sorbance 313 
 10,189 M1 cm1, determined by the total acidiccentrifugation at 11,500  g for 30 min at 4	C, and supernatant was
used for further purification of MRD. hydrolysis of the known amount of MC.
Crystallization and Sample PreparationPurification of MRD
Purification of His6-tagged MRD was carried out by standard meth- Crystallization was accomplished using protein at 3 mg/ml concen-
tration in 55% ammonium sulfate and 100 mM MES at pH 6.0. Nativeods with slight modifications. The supernatant was passed through
a column containing 5 ml of preequilibrated (His buffer) Ni2-NTA crystals were small and frequently twinned. Addition of
-octylglucoside to a final concentration of 0.05% slowed downagarose to bind the His6-tagged MRD, and the resin was washed
with 2 liters of His buffer at 4	C. The bound protein was recovered crystal growth and reduced twining. SeMet crystals grew in similar
conditions, with the exception of a small increase in ammoniumwith elution buffer containing 250 mM imidazole (pH 8.5). The His6-
tag was cleaved with 1 l of rTEV protease (Gibco) per milliliter of sulfate (65%). The SeMet crystals grew more slowly (3–4 weeks)
and were typically single and larger, with maximal dimensions ofsample for 48 hr at room temperature. A 10,000 MWCO Slide-a-
Lyser cassette (Pierce) was used for dialysis against 4 liters of His 0.25  0.15  0.15 mm. SeMet crystals were soaked in mother
liquor with increased ammonium sulfate content (100 mM MES andbuffer to remove imidazole and the cut His6-tag. The dialyzed solu-
tion was passed through a column containing 5ml of Ni2-NTA aga- 75% ammonium sulfate) containing crystalline mitomycin C and
NADH at a concentration of approximately 1–2 mM each. NADHrose to remove both uncut protein and rTEV protease. The protein
was concentrated to3 mg/mL by using an Amicon 8050 ultrafiltra- was used because of previously published data, which suggested
that MC binding by MRD is NADH dependent [16]. However, ourtion unit with a YM 10 membrane (10,000 MWCO; Millipore).
present data show that, in the presence of NADH, MRD binds MC
with a dissociation constant of 24.1 M, i.e., within experimentalMutagenesis and Preparation of SeMet Samples
The L19M and L25M mutations used to introduce additional methio- error the same as in its absence. Soaks without NADH produced
pink MRD crystals in comparable time. Native and soaked SeMetnine residues for phasing purposes, as well as the D52N and Y112F
mutations designed to probe the specificity of the binding site, were crystals were flash frozen using mother liquor solution with high
(70%) ammonium sulfate concentration and 12% v/v glycerol.prepared using QuikChange protocol. All constructs were verified
by direct sequencing prior to further use. To obtain SeMet samples,
the auxotrophic strain B834 was transformed with the pHIS plasmid. Structure Solution and Model Refinement
Data were collected at beamline X9B of the National SynchrotronCultures were grown in LeMaster medium, with selenomethionine
replacing methionine. The expression protocol paralleled that of the Light Source (Brookhaven National Laboratory) using a Quantum 4
ADSC CCD area detector. The apo-MRD data set was collected tonative protein described above, with the important exception that
1 day was required for the culture to reach the necessary optical a resolution of 1.5 A˚, the partial soak to a resolution of 1.3 A˚, and
the full soak to 1.5 A˚. A total of 180 frames were collected for thedensity, instead of several hours. The purification protocol was like-
wise identical, with the exception that the rTEV cleavage reaction high-resolution (1.3 A˚) data set, 1	 rotation each. The unit cell was
identified as C2; a 
 42.5 A˚, b 
 65.3 A˚, c 
 45.3 A˚, and  
 105.6	took nearly a week to run to completion, instead of two days.
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(Vm 
 1.96 A˚3/Da). Data were reduced using HKL [41]. Details are of the acid hydrolysis of mitomycins. J. Am. Chem. Soc. 107,
5182–5186.shown in Table 1. Anomalous differences from the data set pro-
cessed to 1.3 A˚ were used to locate the positions of the three 13. August, P.R., Flickinger, M.C., and Sherman, D.H. (1994). Clon-
ing and analysis of a locus (mcr) involved in mitomycin C resis-selenium atoms using SHELXS [22]. This substructure was used in
MLPHARE, and the phases were modified in DM as implemented tance in S. lavendulae. J. Bacteriol. 176, 4448–4454.
14. August, P.R., Rahn, J.R., Flickinger, M.C., and Sherman, D.H.in CCP4 [42] using standard settings. The resulting density was of
very high quality and was used for automatic model building using (1996). Inducible synthesis of the mitomycin C resistance gene
product (MCRA) from S. lavendulae. Gene 175, 261–267.wARP [21], which placed 110 out of 130 total residues. This model
was used as a starting point in the refinement against all three data 15. Sheldon, P.J., Johnson, D.A., August, P.R., Liu, H., and Sher-
man, D.H. (1997). Characterization of a mitomycin-binding drugsets, initially done with REFMAC [43]. The only significant difference
between the models occurs at residues 66–70, which is the crucial resistance mechanism from the producing organism, Strepto-
myces lavendulae. J. Bacteriol. 179, 1796–1804.connecting region between domains. For each data set, refinement
was done with and without models of these residues to demonstrate 16. Johnson, D.A, August, P.R., Shackleton, C., Liu, H.-w., and Sher-
man, D.H. (1997). Microbial resistance to mitomycins involvesthat the connecting density is not an artifact. Final refinement was
a redox relay mechanism. J. Am. Chem. Soc. 119, 2576–2577.done using SHELXL [22], which was also used for final placement
17. Sheldon, P.J., Mao, Y., He, M., and Sherman, D.H. (1999). Mito-of waters for each model. (For those parts of the DAM model that
mycin C resistance in Streptomyces lavendulae includes a noveldiffer from MC, standard bond angles and distances were used, as
drug-binding-protein-dependent export system. J. Bacteriol.no DAM crystal structure is available.)
181, 2507–2512.
18. Mao, Y., Varoglu, M., and Sherman, D.C. (1999). Molecular char-Figures
acterization and analysis of the biosynthetic gene cluster for theThe figures were prepared using O [44], SETOR [45], and WebLab
antitumor antibiotic mitomycin C from Streptomyces lavendulaeViewerPro (MSI).
NRRL 2564. Chem. Biol. 6, 251–263.
19. Chung-Faye, G., Palmer, D., Anderson, D., Clark, J., Downes,
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Accession Numbers
Atomic coordinates were deposited in the Protein Data Bank under
accession codes 1KMZ (unliganded MRD) and 1KLL (MRD with
bound 1,2-cis-1-hydroxy-2,7-diaminomitosene).
